[
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now?",
    "summary": "We recently compiled a list of the 8 Cash-Rich Dividend Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other cash-rich dividend stocks. Cash remains a critical asset, as companies with strong cash reserves tend to attract investors regardless of the […]",
    "url": "https://finnhub.io/api/news?id=7dae24aa94b10792e8a5d483cb1c56f01eb24ae85441eec67d901135d1100581",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734544161,
      "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now?",
      "id": 132043303,
      "image": "",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 8 Cash-Rich Dividend Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other cash-rich dividend stocks. Cash remains a critical asset, as companies with strong cash reserves tend to attract investors regardless of the […]",
      "url": "https://finnhub.io/api/news?id=7dae24aa94b10792e8a5d483cb1c56f01eb24ae85441eec67d901135d1100581"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=555e4381a99453f07010fd28ca980cdbf812ea25024033188afce9d236cec806",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734540060,
      "headline": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
      "id": 132148495,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=555e4381a99453f07010fd28ca980cdbf812ea25024033188afce9d236cec806"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=c815b2a349279b239fdb2fe3225f14b0e58fcb143a155c3ab59f260e83f4fcb2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734530418,
      "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 132043304,
      "image": "https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=c815b2a349279b239fdb2fe3225f14b0e58fcb143a155c3ab59f260e83f4fcb2"
    }
  },
  {
    "ts": null,
    "headline": "Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth",
    "summary": "Neurocrineâs Crenessity approval for CAH treatment represents a transformative opportunity. See why I maintain my strong buy rating on NBIX stock.",
    "url": "https://finnhub.io/api/news?id=450361bf713a9da2930961e066f5e2dfb6047e4485bc854d2906b4893fc7db43",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734516695,
      "headline": "Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth",
      "id": 132039295,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334434663/image_1334434663.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Neurocrineâs Crenessity approval for CAH treatment represents a transformative opportunity. See why I maintain my strong buy rating on NBIX stock.",
      "url": "https://finnhub.io/api/news?id=450361bf713a9da2930961e066f5e2dfb6047e4485bc854d2906b4893fc7db43"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: Still An Opportunity Yielding Over 4%",
    "summary": "Bristol-Myers' strategic acquisitions are expected to boost future EPS and financial stability. See why I rate BMY stock a strong buy.",
    "url": "https://finnhub.io/api/news?id=454f7b7a10dcf547672f9c868c505b174744c3e45f83732582a4a91d03076465",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734512400,
      "headline": "Bristol-Myers: Still An Opportunity Yielding Over 4%",
      "id": 132038877,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers' strategic acquisitions are expected to boost future EPS and financial stability. See why I rate BMY stock a strong buy.",
      "url": "https://finnhub.io/api/news?id=454f7b7a10dcf547672f9c868c505b174744c3e45f83732582a4a91d03076465"
    }
  }
]